There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases.Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. 1. CertaraCertara (CERT -0.35%) is poised to capitalize on the transform ...

Inspire Medical Systems (INSP) 2025 Conference Summary Company Overview - **Company**: Inspire Medical Systems (INSP) - **Event**: 2025 Conference held on June 17, 2025 Key Points Product Launch and Features - **INSPIRE V Launch**: The launch of INSPIRE V is a significant milestone, showcasing advancements in patient therapy and device technology [2][3] - **Reduced Implant Time**: INSPIRE V has demonstrated a 20% reduction in implant time, enhancing the efficiency of the procedure [3][20] - **Innovative Technology**: The device now incorporates an accelerometer for respiration sensing, eliminating the need for an external pressure sensing lead, which simplifies the implant procedure [5][13] - **Closed Loop Stimulation**: The device is designed to synchronize stimulation with the patient's breathing cycle, preventing muscle fatigue and optimizing treatment for obstructive sleep apnea (OSA) [7][10] Clinical Data and Outcomes - **Clinical Studies**: Data presented at the American Academy of Sleep Medicine meeting indicates improved outcomes with INSPIRE V, including an increase in inspiratory overlap from 78% to 86% [17][18] - **Patient Adherence**: Therapy adherence has been reported at over six hours in initial patients from Singapore, indicating strong patient engagement with the therapy [22][26] - **Surgery Reduction**: A 20% reduction in surgeries from baseline was noted in initial studies, highlighting the device's effectiveness [20] Market Dynamics and Growth Potential - **Surgeon Efficiency**: The new design allows surgeons to perform more procedures in a day, potentially increasing the number of cases handled [36][39] - **Market Demand**: There is a growing demand for Inspire procedures, with existing surgeons expected to increase utilization due to the simplified procedure [41][61] - **Future Growth**: The company anticipates growth rates of 10% to 15% over the next two to three years, driven by improved technology and increased surgeon training [59][63] Challenges and Considerations - **Competition**: The company acknowledges potential rising competition and capacity constraints but remains focused on growth and improving patient outcomes [58][61] - **Transition Period**: The transition from INSPIRE IV to INSPIRE V may cause temporary disruptions, but the company is confident in managing inventory and patient demand [49][50] Financial Outlook - **Revenue Guidance**: The company provided guidance for $10 million to $15 million in revenue shifting from Q2 to Q4, reflecting the transition to INSPIRE V [45][46] - **Profitability Focus**: While growth is prioritized, the company aims to maintain profitability and improve gross margins through operational efficiencies [62][70] Additional Insights - **Patient-Centric Approach**: The focus remains on optimizing patient outcomes and ensuring that the therapy is effective and comfortable for users [26][63] - **Future Innovations**: Inspire Medical Systems is already planning for future iterations of the device, including Inspire VI and VII, to continue advancing their technology [70] This summary encapsulates the key discussions and insights from the Inspire Medical Systems conference, highlighting the company's innovative product developments, market strategies, and future growth potential.

Summary of Inspire Medical Systems (INSP) 2025 Conference Call Company Overview - **Company**: Inspire Medical Systems (INSP) - **Event**: 2025 Conference Call - **Date**: June 13, 2025 Key Points Industry and Market Dynamics - Discussion focused on the **Obstructive Sleep Apnea (OSA)** market and the competitive landscape surrounding it [2][10] - Emphasis on the **Inspire five** launch and its implications for the OSA treatment market [2][10] Inspire Five Launch - **Inspire five** features a **20% reduction in implant time** and improved sensing technology integrated into the neurostimulator [10][26] - The new device incorporates an **accelerometer** for respiration sensing, eliminating the need for a separate pressure sensing lead, thus simplifying the implant procedure [14][21] - The device allows for **Bluetooth communication** with a patient app and integrates with **SleepSync**, a cloud-based patient management system [11][12] Clinical Data and Performance - Clinical trials showed that **Inspire five** improved **inspiratory phase overlap** from **78% to 83%**, enhancing treatment effectiveness [22][24] - A study in Singapore indicated that the average nightly usage post-implant was **six hours**, demonstrating strong patient adherence [27] - The **St. Luke's Health** study reported over **80% success rate** in positional sleep apnea, indicating improved efficacy compared to previous trials [31][32] Surgeon Feedback and Adoption - Surgeons reported positive feedback regarding the ease of implantation without the pressure sensing lead, leading to reduced operating room (OR) time [41][42] - The transition to **Inspire five** is expected to increase the number of procedures performed by surgeons due to improved efficiency [64][70] Financial and Market Outlook - The company anticipates continued growth in adoption of Inspire therapy, with a focus on penetrating the **single-digit percentage** of the overall target market [38][39] - The **2025 guidance** includes expectations for increased capacity and productivity from surgeons, despite some anticipated competitive trials [82][83] Competitive Landscape - The emergence of **GLP-1 medications** for weight management in sleep apnea patients was discussed, with the potential for these treatments to complement Inspire therapy [98][104] - The company is monitoring the impact of GLP-1 on patient demand and treatment eligibility, noting that Inspire therapy remains effective for patients with tongue-based obstruction [100][103] Future Developments - Inspire is already working on **Inspire six**, which aims to enhance therapy adherence by detecting sleep states and automatically adjusting stimulation [90][91] - The integration of **SleepSync** with Inspire five is expected to facilitate better patient management and data collection for future improvements [92] Conclusion - Inspire Medical Systems is positioned for growth with the launch of Inspire five, leveraging advanced technology to improve patient outcomes and streamline surgical procedures. The company is optimistic about its market penetration and future innovations while navigating competitive pressures from emerging therapies.

Investors in Inspire Medical Systems, Inc. (INSP) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 16, 2026 $95 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It ...

Group 1 - The core viewpoint is that the risk-reward proposition for Inspire Medical (NYSE: INSP) has improved due to lagging shares, profitability, and FDA approval for a new device [1] - Inspire Medical's business has become profitable, indicating a positive shift in financial performance [1] - The company received FDA approval for a new device, which is expected to enhance its market position and growth potential [1] Group 2 - The investing group "Value In Corporate Events" focuses on identifying opportunities in IPOs, mergers & acquisitions, earnings reports, and corporate capital allocation changes [2] - The group covers approximately 10 major events each month to find the best investment opportunities [2]

Core Insights - Inspire Medical Systems, Inc. is a medical technology company specializing in innovative, minimally invasive solutions for obstructive sleep apnea [1][3] - The company will present at the Truist Securities MedTech Conference on June 17, 2025, at 11:20 a.m. Eastern Time, with a live webcast available [1][2] Company Overview - Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] - The company focuses on the development and commercialization of its innovative solutions [3]

MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live web ...

Summary of Inspire Medical Systems (INSP) Conference Call Company Overview - **Company**: Inspire Medical Systems (INSP) - **Event**: 2025 Conference on May 13, 2025 - **Key Speakers**: Tim Herbert (Chairman and CEO), Rick Buchholz (CFO), Ez Giajia (VP, Investor Relations) Key Points Industry and Product Launch - Inspire Medical has launched **Inspire five**, a new platform aimed at improving patient outcomes and surgeon efficiency [1][3][12] - The launch is significant as it marks a transition from the previous model, Inspire four, and is expected to enhance the company's growth trajectory [5][30] Financial Performance - In Q1 2025, Inspire reported a **23% growth** and achieved positive earnings for the first time in Q1, indicating strong operational leverage [7][8] - The company anticipates **mid to high single-digit sequential growth** for Q2, with a focus on transitioning to Inspire five [20][21] Market Dynamics - There was a noted **patient warehousing** effect, where patients opted to wait for Inspire five rather than proceed with Inspire four, impacting Q1 performance [10][24] - The company is optimistic about a strong second half of 2025 as the transition to Inspire five is completed [11][19] Marketing and Patient Engagement - Inspire plans to increase **direct-to-patient marketing** efforts to raise awareness and drive patient engagement [6][60] - The company is also focusing on educating healthcare providers, including family practice and sleep physicians, about the benefits of Inspire therapy [60] Surgical Efficiency and Training - The new Inspire five system simplifies the surgical procedure by eliminating the need for a pressure sensing lead, which is expected to reduce surgical time from **60-90 minutes to 45-60 minutes** [46] - Inspire has trained approximately **400 advanced practice providers (APPs)** to assist in patient management and post-operative care, enhancing surgical capacity [47] Future Developments - Inspire is looking ahead to **Inspire six**, which will include features like sleep detection and auto-activation, aimed at improving patient adherence to therapy [63][64] - The company is also exploring a subscription model for patient management through its upcoming **SleepSync** program, which will help sleep physicians manage patients more effectively [66] Financial Outlook - Inspire is committed to balancing growth with profitability, expecting improved margins as utilization increases and customer acquisition costs decrease [58][59] - The company is confident that the transition to Inspire five will lead to higher utilization rates and revenue per sales representative [68] Conclusion - Inspire Medical Systems is positioned for growth with the launch of Inspire five, a focus on patient engagement, and a commitment to improving surgical efficiency. The company is optimistic about its future developments and financial performance as it continues to innovate in the sleep apnea treatment market [73][74]

Core Points - The Dr. Jose Jacob Scholarship for Future Doctors is now open for applications, offering a one-time award of $1,000 to undergraduate students in the U.S. pursuing a career in medicine [1][4] - Founded by Dr. Jose Jacob, a board-certified invasive cardiologist, the scholarship aims to support future medical professionals who show vision, resilience, and dedication [2][5] - Applicants must be on a pre-medical track or pursuing a degree with the intention of applying to medical school, and they are required to submit an original essay on a current medical challenge or opportunity [3][4] Eligibility and Application Process - The scholarship is open to undergraduate students regardless of geographic location, background, or socioeconomic status, encouraging applications from all eligible individuals [6] - The essay must be a maximum of 500 words, showcasing the applicant's insight into medical issues and their commitment to advancing healthcare [3][4] - Applications must be submitted by February 15, 2026, with the winner announced on March 15, 2026 [4] Purpose and Impact - Dr. Jose Jacob aims to encourage engagement with the evolving healthcare landscape and support aspiring medical professionals financially and academically [5] - The scholarship reflects a commitment to shaping the next generation of physicians prepared to tackle modern medical challenges [5][6] - Interested candidates can find more information on eligibility and application guidelines on the official scholarship website [7]

Investors might want to bet on Inspire Medical Systems (INSP) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Indiv ...